Unknown PHASE2 INTERVENTIONAL 3-arm NCT05290220

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (A Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma (HCC)

Sponsor: Shanghai Henlius Biotech

Conditions Advanced Hepatocellular Carcinoma

Interventions HLX04 HLX07 HLX10 lenvatinib

Updated 5 times since 2022 Last updated: May 1, 2022 Started: Aug 1, 2022 Primary completion: Dec 15, 2023 Completion: Dec 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05290220, this PHASE2 trial focuses on Advanced Hepatocellular Carcinoma and remains ongoing. Sponsored by Shanghai Henlius Biotech, it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Apr 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Henlius Biotech

Data source: Shanghai Henlius Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.